The CDK network: Linking cycles of cell sdivision and gene expression

Genes and Cancer

Volumn 3, Issue 11-12, 2012, Pages 731-738

  Fisher, Robert P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CDK activating kinase (CAK); Cell division cycle; Cyclin dependent kinase (CDK); Phosphorylation; RNA polymerase II; Transcription

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; RNA POLYMERASE II;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL VIABILITY; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 84880475258     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912473308     Document Type: Article

References (118)

1. Morgan DO. The cell cycle: principles of control. London: New Science Press Ltd; 2007.
2. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A. 1974;71(4):1286-90.
3. Skotheim JM, Di Talia S, Siggia ED, Cross FR. Positive feedback of G1 cyclins ensures coherent cell cycle entry. Nature. 2008;454(7202):291-6.
4. Yao G, Lee TJ, Mori S, Nevins JR, You L. A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol. 2008;10(4):476-82.
5. Diffley JF. Regulation of early events in chromosome replication. Curr Biol. 2004;14(18):R778-86.
6. Merrick KA, Fisher RP. A virtual cycle: theory and experiment converge on the exit from mitosis. F1000 Biol Rep. 2010;2. pii: 33.
7. Wohlbold L, Fisher RP. Behind the wheel and under the hood: functions of cyclin-dependent kinases in response to DNA damage. DNA Repair (Amst). 2009;8(9):1018-24.
8. Yata K, Esashi F. Dual role of CDKs in DNA repair: to be, or not to be. DNA Repair (Amst). 2009;8(1):6-18.
9. Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol. 2007;8(2):149-60.
10. Loog M, Morgan DO. Cyclin specificity in the phosphorylation of cyclin-dependent kinase substrates. Nature. 2005;434(7029):104-8.
11. Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999;18(6):1571-83.
12. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997;11(7):847-62.
13. Chen J, Larochelle S, Li X, Suter B. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature. 2003;424:228-32.
14. Miller ME, Cross FR. Mechanisms controlling subcellular localization of the G(1) cyclins Cln2p and Cln3p in budding yeast. Mol Cell Biol. 2001;21(18):6292-311.
15. Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci. 2005;118(Pt 22):5171-80.
16. Buratowski S. Progression through the RNA polymerase II CTD cycle. Mol Cell. 2009;36(4): 541-6.
17. Phatnani HP, Greenleaf AL. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 2006;20(21):2922-36.
18. Sansó M, Lee KM, Viladevall L, et al. A positive feedback loop links opposing functions of P-TEFb/Cdk9 and histone H2B ubiquitylation to regulate transcript elongation in fission yeast. PLoS Genet. 2012;8(8):e1002822.
19. Shchebet A, Karpiuk O, Kremmer E, Eick D, Johnsen SA. Phosphorylation by cyclindependent kinase-9 controls ubiquitin-conjugating enzyme-2A function. Cell Cycle. 2012;11(11): 2122-7.
20. Wood A, Schneider J, Dover J, Johnston M, Shilatifard A. The Bur1/Bur2 complex is required for histone H2B monoubiquitination by Rad6/ Bre1 and histone methylation by COMPASS. Mol Cell. 2005;20(4):589-99.
21. Hautbergue G, Goguel V. The yeast C-type cyclin Ctk2p is phosphorylated and rapidly degraded by the ubiquitin-proteasome pathway. Mol Cell Biol. 1999;19(4):2527-34.
22. Shimanuki M, Chung SY, Chikashige Y, et al. Two-step, extensive alterations in the transcriptome from G0 arrest to cell division in Schizosaccharomyces pombe. Genes Cells. 2007;12(5):677-92.
23. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature. 2001;414(6861):322-5.
24. Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature. 2001;414(6861):317-22.
25. Yang Z, Yik JH, Chen R, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535-45.
26. Espinoza FHE, Farrell A, Nourse JL, Chamberlin HM, Gileadi O, Morgan DO. Cak1 is required for Kin28 phosphorylation and activation in vivo. Mol Cell Biol. 1998;18:6365-73.
27. Hermand D, Pihlak A, Westerling T, et al. Fission yeast Csk1 is a CAK-activating kinase (CAKAK). EMBO J. 1998;17:7230-8.
28. Kimmelman J, Kaldis P, Hengartner CJ, et al. Activating phosphorylation of the kin28p subunit of yeast TFIIH by cak1p. Mol Cell Biol. 1999;19:4774-87.
29. Larochelle S, Amat R, Glover-Cutter K, et al. Cyclin-dependent kinase control of the initiationto- elongation switch of RNA polymerase II. Nat Struct Mol Biol. 2012;11:1108-15.
30. Lee KM, Saiz JE, Barton WA, Fisher RP. Cdc2 activation in fission yeast depends on Mcs6 and Csk1, two partially redundant Cdk-activating kinases CAKs). Curr Biol. 1999;9:441-4.
31. Ostapenko D, Solomon MJ. Phosphorylation by Cak1 regulates the C-terminal domain kinase Ctk1 in saccharomyces cerevisiae. Mol Cell Biol. 2005;25:3906-13.
32. Pei Y, Du H, Singer J, et al. Cyclin-dependent kinase 9 (Cdk9) of fission yeast is activated by the CDK-activating kinase Csk1, overlaps functionally with the TFIIH-associated kinase Mcs6, and associates with the mRNA cap methyltransferase Pcm1 in vivo. Mol Cell Biol. 2006;26:777-88.
33. Yao S, Prelich G. Activation of the Bur1-Bur2 cyclin-dependent kinase complex by Cak1. Mol Cell Biol. 2002;22:6750-8.
34. Qiu H, Hu C, Hinnebusch AG. Phosphorylation of the Pol II CTD by KIN28 enhances BUR1/ BUR2 recruitment and Ser2 CTD phosphorylation near promoters. Mol Cell. 2009;33(6): 752-62.
35. Viladevall L, St Amour CV, Rosebrock A, et al. TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Mol Cell. 2009;33(6):738-51.
36. Czudnochowski N, Bosken CA, Geyer M. Serine- 7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. Nat Commun. 2012;3:842.
37. St Amour CV, Sanso M, Bosken CA, et al. Separate domains of fission yeast Cdk9 (P-TEFb) are required for capping enzyme recruitment and primed (Ser7-phosphorylated) Rpb1 carboxylterminal domain substrate recognition. Mol Cell Biol. 2012;32(13):2372-83.
38. Harper JW, Elledge SJ. The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev. 1998;12:285-9.
39. Larochelle S, Merrick KA, Terret ME, et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell. 2007;25(6):839-50.
40. Merrick KA, Larochelle S, Zhang C, Allen JJ, Shokat KM, Fisher RP. Distinct activation pathways confer cyclin binding selectivity on Cdk1 and Cdk2 in human cells. Mol Cell. 2008;32: 662-72.
41. Ali S, Heathcote DA, Kroll SH, et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009;69(15):6208-15.
42. Lolli G, Johnson LN. CAK-cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle. 2005;4(4):572-7.
43. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell. 2006;23(3):297-305.
44. Chen R, Yang Z, Zhou Q. Phosphorylated positive transcription elongation factor b (P-TEFb) is tagged for inhibition through association with 7SK snRNA. J Biol Chem. 2004;279(6):4153-60.
45. 2+ signaling. Genes Dev. 2008;22(10):1356-68.
46. Glover-Cutter K, Larochelle S, Erickson B, et al. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol. 2009;29(20):5455-64.
47. Adelman K, Lis JT. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat Rev Genet. 2012;13(10):720-31.
48. Gilchrist DA, Dos Santos G, Fargo DC, et al. Pausing of RNA polymerase II disrupts DNAspecified nucleosome organization to enable precise gene regulation. Cell. 2010;143(4):540-51.
49. Gilchrist DA, Fromm G, dos Santos G, et al. Regulating the regulators: the pervasive effects of Pol II pausing on stimulus-responsive gene networks. Genes Dev. 2012;26(9):933-44.
50. Fuda NJ, Ardehali MB, Lis JT. Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature. 2009;461(7261):186-92.
51. Perales R, Bentley D. "Cotranscriptionality": the transcription elongation complex as a nexus for nuclear transactions. Mol Cell. 2009;36(2):178-91.
52. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 2006;20(5):601-12.
53. Meyer KD, Lin SC, Bernecky C, Gao Y, Taatjes DJ. p53 activates transcription by directing structural shifts in Mediator. Nat Struct Mol Biol. 2010;17(6):753-60.
54. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclindependent kinases by the CDK-activating kinase. J Biol Chem. 1995;270:18195-7.
55. Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell. 1994;78:713-24.
56. Matsuoka M, Kato J, Fisher RP, Morgan DO, Sherr CJ. Activation of cyclin-dependent kinase-4 (CDK4) by mouse MO15-associated kinase. Mol Cell Biol. 1994;14:7265-75.
57. Larochelle S, Batliner J, Gamble MJ, et al. Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol. 2006;13:55-62.
58. Espinoza FH, Farrell A, Erdjument-Bromage H, Tempst P, Morgan DO. A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science. 1996;273:1714-7.
59. Kaldis P, Sutton A, Solomon MJ. The Cdk-activating kinase (CAK) from budding yeast. Cell. 1996;86:553-64.
60. Thuret J-Y, Valay J-G, Faye G, Mann C. Civ1 (CAK in vivo), a novel Cdk-activating kinase. Cell. 1996;86:565-76.
61. Larochelle S, Pandur J, Fisher RP, Salz HK, Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev. 1998;12:370-81.
62. Wallenfang MR, Seydoux G. cdk-7 is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A. 2002;99:5527-32.
63. Abbas T, Jha S, Sherman NE, Dutta A. Autocatalytic phosphorylation of CDK2 at the activating Thr160. Cell Cycle. 2007;6(7):843-52.
64. Baumli S, Lolli G, Lowe ED, et al. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 2008;27(13):1907-18.
65. Ganuza M, Saiz-Ladera C, Canamero M, et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J. 2012;31(11):2498-510.
66. Ganuza M, Santamaria D. Cdk7: open questions beyond the prevailing model. Cell Cycle. 2012;11(19).
67. Sherr CJ. Mammalian G1 cyclins. Cell. 1993;73:1059-65.
68. Bockstaele L, Kooken H, Libert F, et al. Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors". Mol Cell Biol. 2006;26(13):5070-85.
69. Kato J, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 Kip1) of cyclin-dependent kinase-4 activation. Cell. 1994;79:487-96.
70. Rocha AS, Paternot S, Coulonval K, Dumont JE, Soares P, Roger PP. Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell. 2008;19(11):4814-25.
71. Day PJ, Cleasby A, Tickle IJ, et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci U S A. 2009;106(11):4166-70.
72. Takaki T, Echalier A, Brown NR, Hunt T, Endicott JA, Noble ME. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci U S A. 2009;106(11):4171-6.
73. Russo AA, Jeffrey PD, Pavletich NP. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol. 1996;3:696-700.
74. Kato J-Y, Matsuoka M, Strom DK, Sherr CJ. Regulation of cyclin D-dependent kinases (cdk4) by cdk4-activating kinase. Mol Cell Biol. 1994;14:2713-21.
75. Bockstaele L, Bisteau X, Paternot S, Roger PP. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol Cell Biol. 2009;29(15):4188-200.
76. Murray AW, Marks D. Can sequencing shed light on cell cycling? Nature. 2001;409:844-6.
77. Merrick KA, Fisher RP. Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle. Cell Cycle. 2010;9(4):706-14.
78. Merrick KA, Wohlbold L, Zhang C, et al. Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell. 2011;42(5):624-36.
79. Katsuno Y, Suzuki A, Sugimura K, et al. Cyclin A-Cdk1 regulates the origin firing program in mammalian cells. Proc Natl Acad Sci U S A. 2009;106(9):3184-9.
80. Koseoglu MM, Graves LM, Marzluff WF. Phosphorylation of threonine 61 by cyclin a/ Cdk1 triggers degradation of stem-loop binding protein at the end of S phase. Mol Cell Biol. 2008;28(14):4469-79.
81. Chung JH, Bunz F. Cdk2 is required for p53- independent G2/M checkpoint control. PLoS Genet. 2010;6(2):e1000863.
82. Wohlbold L, Merrick KA, De S, et al. Chemical genetics reveals a specific requirement for cdk2 activity in the DNA damage response and identifies nbs1 as a cdk2 substrate in human cells. PLoS Genet. 2012;8(8):e1002935.
83. Coulonval K, Kooken H, Roger PP. Coupling of T161 and T14 phosphorylations protects cyclin B-CDK1 from premature activation. Mol Biol Cell. 2011;22(21):3971-85.
84. Cheng A, Kaldis P, Solomon MJ. Dephosphorylation of human cyclin-dependent kinases by protein phosphatase type 2C alpha and beta 2 isoforms. J Biol Chem. 2000;275(44):34744-9.
85. Cheng A, Ross KE, Kaldis P, Solomon MJ. Dephosphorylation of cyclin-dependent kinases by type 2C protein phosphatases. Genes Dev. 1999;13(22):2946-57.
86. Poon RYC, Hunter T. Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinaseinteracting phosphatase KAP in the absence of cyclin. Science. 1995;270:90-3.
87. Larochelle S, Chen J, Knights R, et al. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J. 2001;20:3749-59.
88. Sherr CJ, Roberts JM. Inhibitors of mammalian G 1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-63.
89. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007;128(2):281-94.
90. Grimmler M, Wang Y, Mund T, et al. Cdkinhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007;128(2):269-80.
91. James MK, Ray A, Leznova D, Blain SW. Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol. 2008;28(1):498-510.
92. Ray A, James MK, Larochelle S, Fisher RP, Blain SW. p27Kip1 inhibits cyclin Dcyclin- dependent kinase 4 by two independent modes. Mol Cell Biol. 2009;29(4):986-99.
93. Ross KE, Kaldis P, Solomon MJ. Activating phosphorylation of the Saccharomyces cerevisiae cyclin-dependent kinase, Cdc28p, precedes cyclin binding. Mol Biol Cell. 2000;11:1597-609.
94. Tsakraklides V, Solomon MJ. Comparison of Cak1p-like cyclin-dependent kinase-activating kinases. J Biol Chem. 2002;277(36):33482-9.
95. Saiz JE, Fisher RP. A CDK-activating kinase network is required in cell cycle control and transcription in fission yeast. Curr Biol. 2002;12:1100-5.
96. Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448(7155):811-5.
97. Madhani HD, Styles CA, Fink GR. MAP kinases with distinct inhibitory functions impart signaling specificity during yeast differentiation. Cell. 1997;91:673-84.
98. Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005;7(8):831-6.
99. Merrick KA, Fisher RP. Why minimal is not optimal: driving the mammalian cell cycle-and drug discovery-with a physiologic CDK control network. Cell Cycle. 2012;11(14):2600-5
100. Fesquet D, Labbé J-C, Derancourt J, et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 1993;12:3111-21.
101. Mäkelä TP, Tassan J-P, Nigg EA, Frutiger S, Hughes GJ, Weinberg RA. A cyclin associated with the CDK-activating kinase MO15. Nature. 1994;371:254-7.
102. Solomon MJ, Harper JW, Shuttleworth J. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J. 1993;12:3133-42.
103. Feaver WJ, Svejstrup JQ, Henry NL, Kornberg RD. Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH/TFIIK. Cell. 1994;79:1103-9.
104. Roy R, Adamczewski JP, Seroz T, et al. The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor. Cell. 1994;79:1093-101.
105. Serizawa H, Mäkelä TP, Conaway JW, Conaway RC, Weinberg RA, Young RA. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature. 1995;374:280-2.
106. Shiekhattar R, Mermelstein F, Fisher RP, et al. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature. 1995;374(6519):283-7.
107. Garrett S, Barton WA, Knights R, Jin P, Morgan DO, Fisher RP. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T-loop. Mol Cell Biol. 2001;21:88-99.
108. Cobrinik D. Pocket proteins and cell cycle control. Oncogene. 2005;24(17):2796-809.
109. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci. 2004;117(Pt 11):2173-81.
110. Burke JR, Deshong AJ, Pelton JG, Rubin SM. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J Biol Chem. 2010;285(21):16286-93.
111. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18(2):753-61.
112. Rubin SM, Gall AL, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylationinduced E2F release. Cell. 2005;123(6):1093-106.
113. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997;272(19):12738-46.
114. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat Struct Mol Biol. 2010;17(2):194-201.
115. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910-7.
116. Nevins JR. Cell cycle targets of the DNA tumor viruses. Curr Opin Genet Dev. 1994;4(1):130-4.
117. Sherr CJ. Cancer cell cycles. Science. 1996; 274:1672-7.
118. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323-30.